Rein Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Voss Value Master Fund, LP | — | Purchase | 104,183 | $1.22 | $127,103 | 926,441 | Nov 14, 2025 |
| Voss Value-Oriented Special Situations Fund, LP | — | Purchase | 178,392 | $1.39 | $247,965 | 500,000 | Oct 24, 2025 |
| WINDSOR JAMES BRIAN | President and CEO | Purchase | 161 | $2.25 | $362 | 161 | Dec 5, 2024 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | — | Sale | 1,900 | $3.30 | $6,270 | 1,751,256 | Jun 17, 2024 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | — | Sale | 5,250 | $3.25 | $17,063 | 1,763,000 | Jun 12, 2024 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | — | Sale | 3,184 | $3.30 | $10,507 | 1,779,567 | Jun 5, 2024 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | — | Sale | 3,100 | $4.10 | $12,710 | 1,807,357 | May 1, 2024 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | — | Sale | 274 | $4.93 | $1,351 | 1,803,503 | Apr 29, 2024 |
| WINDSOR JAMES BRIAN | President and COO | Option Exercise | 2,000 | — | — | 7,122 | Mar 5, 2024 |
| WINDSOR JAMES BRIAN | President and COO | Purchase | 225 | $3.37 | $758 | 225 | Dec 15, 2023 |
| WINDSOR JAMES BRIAN | President and COO | Purchase | 5,076 | $1.97 | $10,000 | 5,122 | Nov 20, 2023 |
| Satter Muneer A | See Remarks | Purchase | 9,000,000 | $1.10 | $9,900,000 | 16,609,449 | Jan 8, 2021 |
| Ambros Reinhard J. | — | Purchase | 5,800 | $1.22 | $7,076 | 5,800 | Jun 15, 2020 |
| VON RICKENBACH JOSEF H | — | Purchase | 227,272 | $1.10 | $249,999 | 445,460 | Jun 8, 2020 |
| Satter Muneer A | — | Purchase | 3,700,000 | $1.10 | $4,070,000 | 7,609,449 | Jun 8, 2020 |
| Bailey Jeffrey Allen | — | Purchase | 39,142 | $0.51 | $19,962 | 74,894 | Nov 14, 2019 |
| Bailey Jeffrey Allen | — | Purchase | 19,894 | $0.53 | $10,544 | 19,894 | Nov 12, 2019 |
| VON RICKENBACH JOSEF H | — | Purchase | 25,000 | $0.97 | $24,250 | 218,188 | Sep 12, 2019 |
| VON RICKENBACH JOSEF H | — | Purchase | 23,225 | $0.71 | $16,490 | 105,043 | Sep 4, 2019 |
| VON RICKENBACH JOSEF H | — | Purchase | 15,000 | $0.73 | $10,950 | 68,352 | Sep 3, 2019 |
| VON RICKENBACH JOSEF H | — | Purchase | 3,600 | $0.77 | $2,772 | 53,352 | Aug 29, 2019 |
| Vukovic Vojo | SVP, Chief Medical Officer | Purchase | 75,000 | $0.59 | $44,250 | 75,000 | Aug 16, 2019 |
| Gregory Kathryn | SVP, Chief Business Officer | Purchase | 45,000 | $0.65 | $29,250 | 45,000 | Aug 13, 2019 |
| NOVARTIS AG | — | Sale | 106,540 | $1.85 | $197,099 | 2,100,004 | Apr 1, 2019 |
| Novartis Bioventures Ltd | — | Sale | 43,800 | $1.92 | $84,096 | 2,206,544 | Mar 13, 2019 |
| NOVARTIS AG | — | Sale | 20,388 | $2.30 | $46,892 | 2,396,882 | Aug 20, 2018 |
| NOVARTIS AG | — | Sale | 8,808 | $2.10 | $18,497 | 2,425,970 | Aug 17, 2018 |
| Novartis Bioventures Ltd | — | Sale | 2,635 | $2.15 | $5,665 | 2,434,778 | Aug 14, 2018 |
| Novartis Bioventures Ltd | — | Sale | 5,615 | $2.44 | $13,701 | 2,442,313 | Aug 13, 2018 |
| LONGENECKER JOHN P PHD | President and CEO | Purchase | 10,000 | $2.45 | $24,500 | 10,000 | Aug 10, 2018 |
| NOVARTIS AG | — | Sale | 1,000 | $2.78 | $2,780 | 2,448,163 | Aug 9, 2018 |
| NOVARTIS AG | — | Sale | 1,739 | $2.97 | $5,165 | 2,449,163 | Aug 6, 2018 |
| NOVARTIS AG | — | Sale | 4,702 | $3.33 | $15,658 | 2,453,844 | Aug 2, 2018 |
| Novartis Bioventures Ltd | — | Sale | 8,181 | $3.22 | $26,343 | 2,458,546 | Jul 31, 2018 |
| Novartis Bioventures Ltd | — | Sale | 2,000 | $3.27 | $6,540 | 2,471,227 | Jul 27, 2018 |
| Novartis Bioventures Ltd | — | Sale | 12,460 | $3.84 | $47,846 | 2,487,622 | Jul 26, 2018 |
| NOVARTIS AG | — | Sale | 30,600 | $4.25 | $130,050 | 2,500,782 | Jul 24, 2018 |
| Novartis Bioventures Ltd | — | Sale | 12,500 | $4.71 | $58,875 | 2,531,382 | Jul 16, 2018 |
| Apple Tree Partners II - Annex, L.P. | — | Other | 655,797 | — | — | — | Jul 6, 2018 |
| APPLE TREE PARTNERS II LP | — | Other | 1,380,241 | — | — | — | Jul 6, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 913 | $5.86 | $5,350 | 1,390,769 | Jun 26, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 1,447 | $5.30 | $7,669 | 1,486,498 | Jun 20, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 1,432 | $5.35 | $7,661 | 1,493,284 | Jun 15, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 10,843 | $5.40 | $58,552 | 1,502,677 | Jun 12, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 9,617 | $5.40 | $51,932 | 1,532,045 | Jun 11, 2018 |
| Dougherty Donald | SVP & Chief Financial Officer | Purchase | 3,000 | $5.40 | $16,200 | 5,000 | Jun 8, 2018 |
| Aivado Manuel | See Remarks | Purchase | 1,000 | $5.61 | $5,610 | 1,000 | Jun 6, 2018 |
| Dougherty Donald | SVP & Chief Financial Officer | Purchase | 2,000 | $5.24 | $10,480 | 2,000 | Jun 1, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 3,105 | $7.05 | $21,890 | 1,646,481 | Apr 19, 2018 |
| APPLE TREE PARTNERS II LP | — | Sale | 150,000 | $9.80 | $1,470,000 | 1,649,586 | Jan 9, 2018 |